Targeted Therapeutics Market

Table of Contents

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Intended Audience
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Market Size and Evolution

Chapter 3 Market Overview

Cancer Burden
Causes of Cancer

• Genetic Factors
• Lifestyle Factors
• Environmental Factors

Cancer-Causing Genes
Immune System and Cancer
Cancer Prevention
Types of Cancer Treatment

• Non-pharmacological Approaches
• Pharmacological Approaches
• Gene Therapy

Market Dynamics

• Drivers
• Restraints
• Opportunity

Chapter 4 Impact of COVID-19 on Market

Overview

• Current Outlook

Impact of COVID-19 on Cancer Care

Chapter 5 Regulatory Aspects

Overview
United States

• New Drug Application (NDA)
• Fast-Track Status

Europe
Japan
India

• New Drug Approval
• Import Registration Certificate
• Import License

China

Chapter 6 Market Breakdown by Type of Targeted Therapy

Overview
Small Molecules

• Market Size and Forecast
• Market Analysis

Monoclonal Antibodies

• Market Size and Forecast
• Market Analysis

Chapter 7 Market Breakdown by Application

Overview
Lung Cancer

• Market Size and Forecast
• Market Analysis

Breast Cancer

• Market Size and Forecast
• Market Analysis

Blood Cancer

• Market Size and Forecast
• Market Analysis

Colorectal Cancer

• Market Size and Forecast
• Market Analysis

Other Cancers

• Market Size and Forecast
• Market Analysis

Chapter 8 Market Breakdown by Region

Introduction
North America

• Market Analysis
• U.S.
• Canada

Europe

• Market Impact
• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific

• Market Analysis
• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Market Size and Forecast

Chapter 9 Industry Structure

Company Landscape
Pipeline Analysis

• Phase I Clinical Trials
• Phase II Clinical Trials
• Phase III Clinical Trials
• Phase IV Clinical Trials

Chapter 10 Company Profiles

AMGEN INC.
ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB
F. HOFFMANN-LA ROCHE LTD.
MERCK & CO., INC.
NOVARTIS AG
PFIZER
TAKEDA PHARMACEUTICAL CO., LTD.
Chapter 11 Appendix: Acronyms

List of Tables

Summary Table : Global Market for Targeted Therapeutics, by Type, Through 2026
Table 1 : Cancer Treatment Types
Table 2 : Cancer Treatment Strategy Timeline
Table 3 : List of Cancer Drug/Imaging Agent Approvals, 2020
Table 4 : Patent Expiration Dates, Targeted Therapy Drugs
Table 5 : Side Effects of Targeted Therapies
Table 6 : Coronavirus Reported Cases and Deaths, by Country, 2020
Table 7 : FDA Approval Date, Selected Targeted Therapeutic Drugs
Table 8 : Global Market for Targeted Therapeutics, by Type, Through 2026
Table 9 : Global Market for Cancer Small Molecule Therapy, by Region, Through 2026
Table 10 : Selected Small Molecule Inhibitors for Cancer Therapy
Table 11 : Global Market for Cancer Monoclonal Antibody Therapy, by Region, Through 2026
Table 12 : Selected Approved/Under-Review MAB Cancer Therapeutics in the U.S. and EU
Table 13 : Global Market for Targeted Therapeutics, by Application, Through 2026
Table 14 : Global Market for Targeted Therapeutics for Lung Cancer, by Region, Through 2026
Table 15 : Some Targeted Therapeutics for Lung Cancer
Table 16 : Global Market for Targeted Therapeutics for Breast Cancer, by Region, Through 2026
Table 17 : Global Market for Targeted Therapeutics for Blood Cancer, by Region, Through 2026
Table 18 : Global Market for Targeted Therapeutics for Colorectal Cancer, by Region, Through 2026
Table 19 : Global Market for Targeted Therapeutics for Other Types of Cancer, by Region, Through 2026
Table 20 : Global Market for Targeted Therapeutics, by Region, Through 2026
Table 21 : North American Market for Targeted Therapeutics, by Type, Through 2026
Table 22 : North American Market for Targeted Therapeutics, by Application, Through 2026
Table 23 : North American Market for Targeted Therapeutics, by Country, Through 2026
Table 24 : European Market for Targeted Therapeutics, by Type, Through 2026
Table 25 : European Market for Targeted Therapeutics, by Application, Through 2026
Table 26 : European Market for Targeted Therapeutics, by Country, Through 2026
Table 27 : Asia-Pacific Market for Targeted Therapeutics, by Type, Through 2026
Table 28 : Asia-Pacific Market for Targeted Therapeutics, by Application, Through 2026
Table 29 : Asia-Pacific Market for Targeted Therapeutics, by Country, Through 2026
Table 30 : Rest of the World Market for Targeted Therapeutics, by Type, Through 2026
Table 31 : Rest of the World Market for Targeted Therapeutics, by Application, Through 2026
Table 32 : Revenue: Selected Targeted Therapeutics, 2019 and 2020
Table 33 : Oncology Drug Licensing Deals, 2020
Table 34 : Oncology Merger and Acquisition Deals, 2020
Table 35 : Selected Targeted Therapeutics in Phase I Clinical Trials, 2021
Table 36 : Selected Targeted Therapeutics in Phase II Clinical Trials, 2021
Table 37 : Selected Targeted Therapeutics in Phase III Clinical Trials, 2021
Table 38 : Selected Targeted Therapeutics in Phase IV Clinical Trials, 2021
Table 39 : Amgen Inc.: Marketed Products, 2020
Table 40 : AstraZeneca: Marketed Products, 2020
Table 41 : Bayer AG: Marketed Products, 2020
Table 42 : Boehringer Ingelheim International GmbH: Marketed Products, 2020
Table 43 : Bristol-Myers Squibb: Marketed Products, 2020
Table 44 : Bristol-Myers Squibb: Selected Product Approvals, 2020-2021
Table 45 : F. Hoffmann-La Roche Ltd.: Marketed Products, 2020
Table 46 : Merck & Co., Inc.: Marketed Products, 2020
Table 47 : Merck & Co., Inc.: Selected Product Approvals, 2020
Table 48 : Novartis AG: Marketed Products, 2020
Table 49 : Pfizer: Marketed Products, 2020
Table 50 : Takeda Pharmaceutical Co., Ltd.: Marketed Products, 2020
Table 51 : Takeda Pharmaceutical Co., Ltd.: Selected Product Approval, 2020-2021
Table 52 : Acronyms Used in This Report

List of Figures

Summary Figure : Global Market Shares of Targeted Therapeutics, by Type, 2020
Figure 1 : Global Estimated Cancer Cases, All Ages, by Cancer Type, 2020
Figure 2 : Global Estimated Cancer Cases, All Ages, 2020
Figure 3 : Global Estimated Cancer Related Deaths, All Ages, 2020
Figure 4 : Distribution of New Cancer Cases in Women, 2020
Figure 5 : Distribution of New Cancer Cases in Men, 2020
Figure 6 : Global Estimated New Cancer Cases, by Region, 2020 vs. 2040
Figure 7 : National Cancer Institute Research Funding, 2012-2019
Figure 8 : Global Market Shares of Targeted Therapeutics, by Type, 2020
Figure 9 : Global Market for Cancer Small Molecule Therapy, 2019-2026
Figure 10 : Global Market for Cancer Small Molecule Therapy, by Region, 2019-2026
Figure 11 : Global Market for Cancer Monoclonal Antibody Therapy, 2019-2026
Figure 12 : Global Market for Cancer Monoclonal Antibody Therapy, by Region, 2019-2026
Figure 13 : Approved Antibody Therapeutics in the U.S. and EU, 2010-2020
Figure 14 : Global Market Shares of Targeted Therapeutics, by Application, 2020
Figure 15 : Global Market for Targeted Therapeutics for Lung Cancer, 2019-2026
Figure 16 : Global Market for Targeted Therapeutics for Lung Cancer, by Region, 2019-2026
Figure 17 : Prevalence of Lung Cancer Cases, by Continent, 2015-2020
Figure 18 : Global Market for Targeted Therapeutics for Breast Cancer, 2019-2026
Figure 19 : Global Market for Targeted Therapeutics for Breast Cancer, by Region, 2019-2026
Figure 20 : Prevalence of Breast Cancer Cases, by Continent, 2015-2020
Figure 21 : Global Market for Targeted Therapeutics for Blood Cancer, 2019-2026
Figure 22 : Global Market for Targeted Therapeutics for Blood Cancer, by Region, 2019-2026
Figure 23 : Share of New Blood Cancer Cases in the U.S., by Cancer Type, 2021
Figure 24 : Global Market for Targeted Therapeutics for Colorectal Cancer, 2019-2026
Figure 25 : Global Market for Targeted Therapeutics for Colorectal Cancer, by Region, 2019-2026
Figure 26 : Prevalence of Colorectal Cancer Cases, by Continent, 2015-2020
Figure 27 : Global Market for Targeted Therapeutics for Other Types of Cancer, 2019-2026
Figure 28 : Global Market for Targeted Therapeutics for Other Types of Cancer, by Region, 2019-2026
Figure 29 : Global Market for Targeted Therapeutics, by Region, 2019-2026
Figure 30 : North American Market Shares of Targeted Therapeutics, by Type, 2020
Figure 31 : North American Market Shares of Targeted Therapeutics, by Application, 2020
Figure 32 : North American Market Shares of Targeted Therapeutics, by Country, 2020
Figure 33 : U.S. Market for Targeted Therapeutics, 2019-2026
Figure 34 : Canadian Market for Targeted Therapeutics, 2019-2026
Figure 35 : European Market Shares of Targeted Therapeutics, by Type, 2020
Figure 36 : European Market Shares of Targeted Therapeutics, by Application, 2020
Figure 37 : European Market Shares of Targeted Therapeutics, by Country, 2020
Figure 38 : German Market for Targeted Therapeutics, 2019-2026
Figure 39 : U.K. Market for Targeted Therapeutics, 2019-2026
Figure 40 : French Market for Targeted Therapeutics, 2019-2026
Figure 41 : Italian Market for Targeted Therapeutics, 2019-2026
Figure 42 : Spanish Market for Targeted Therapeutics, 2019-2026
Figure 43 : Rest of European Market for Targeted Therapeutics, 2019-2026
Figure 44 : Asia-Pacific Market Shares of Targeted Therapeutics, by Type, 2020
Figure 45 : Asia-Pacific Market Shares of Targeted Therapeutics, by Application, 2020
Figure 46 : Asia-Pacific Market Shares of Targeted Therapeutics, by Country, 2020
Figure 47 : Chinese Market for Targeted Therapeutics, 2019-2026
Figure 48 : Indian Market for Targeted Therapeutics, 2019-2026
Figure 49 : Japanese Market for Targeted Therapeutics, 2019-2026
Figure 50 : Rest of Asia-Pacific Market for Targeted Therapeutics, 2020-2026
Figure 51 : Rest of the World Market Shares of Targeted Therapeutics, by Type, 2020
Figure 52 : Rest of the World Market Shares of Targeted Therapeutics, by Application, 2020
Figure 53 : Company Share Analysis of the Global Targeted Therapeutics Market, 2020
Figure 54 : Distribution of Clinical Trials on Targeted Therapeutics, by Phase, 2021
Figure 55 : Amgen Inc.: Annual Revenue, 2018-2020
Figure 56 : Amgen Inc.: Revenue Share, by Product Sales, 2020
Figure 57 : Amgen Inc.: Revenue Share, by Geography, 2020
Figure 58 : AstraZeneca: Annual Revenue, 2018-2020
Figure 59 : AstraZeneca: Oncology Segment Revenue, 2018-2020
Figure 60 : AstraZeneca: Revenue Share, by Geography, 2020
Figure 61 : Bayer AG: Annual Revenue, 2018-2020
Figure 62 : Bayer AG: Revenue Share, by Segment, 2020
Figure 63 : Bayer AG: Revenue Share, by Geography, 2020
Figure 64 : Boehringer Ingelheim International GmbH: Annual Revenue, 2018-2020
Figure 65 : Boehringer Ingelheim International GmbH: Revenue Share, by Segment, 2020
Figure 66 : Boehringer Ingelheim International GmbH: Revenue Share, by Geography, 2020
Figure 67 : Bristol-Myers Squibb: Annual Revenue, 2018-2020
Figure 68 : Bristol-Myers Squibb: Revenue Share, by Geography, 2020
Figure 69 : F. Hoffmann-La Roche Ltd.: Annual Revenue, 2018-2020
Figure 70 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Segment, 2020
Figure 71 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Geography, 2020
Figure 72 : Merck & Co., Inc.: Annual Revenue, 2018-2020
Figure 73 : Merck & Co., Inc.: Revenue Share, by Segment, 2020
Figure 74 : Merck & Co., Inc.: Revenue Share, by Geography, 2020
Figure 75 : Novartis AG: Financial Performance, 2018-2020
Figure 76 : Novartis AG: Revenue Share, by Segment, 2020
Figure 77 : Novartis AG: Revenue Share, by Geography, 2020
Figure 78 : Pfizer: Annual Revenue, 2018-2020
Figure 79 : Pfizer: Oncology Segment Revenue, 2018-2020
Figure 80 : Pfizer: Revenue Share, by Geography, 2020
Figure 81 : Takeda Pharmaceutical Co., Ltd.: Annual Revenue, 2018-2020
Figure 82 : Takeda Pharmaceutical Co., Ltd.: Revenue Share, by Segment, 2020
Figure 83 : Takeda Pharmaceutical Co., Ltd.: Revenue Share, by Geography, 2020

当レポートのプレスリリースは発行されておりません。